WORLDWIDE‑CORRUPTION

China · State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) · Abuse of a dominant market position

南京宁卫医药有限公司

Why it is here

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — abuse of a dominant market position (上海市市场监督管理局 · 沪市监反垄处〔2021〕3220190101511号 · 市场监管总局发布南京宁卫医药有限公司滥用市场支配地位案行政处罚决定书), from 18 November 2021.

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — Abuse of a dominant market position.

Details

Company
南京宁卫医药有限公司
Authority
State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn)
Decision
Abuse of a dominant market position
Grounds and details, as published
上海市市场监督管理局 · 沪市监反垄处〔2021〕3220190101511号 · 市场监管总局发布南京宁卫医药有限公司滥用市场支配地位案行政处罚决定书
From
18 November 2021
Until
—
Status
End date not published
Source
https://www.samr.gov.cn/fldys/tzgg/xzcf/art/2023/art_ed46bf2c7eda41d9a3d69ecdf7560b5a.html
Licence
Public antitrust decisions published by the State Administration for Market Regulation of China (samr.gov.cn/fldys)

SourceState Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) · Abuse of a dominant market position